A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 10 mg Once-daily in the Treatment of Non-Erosive Gastroesophageal Reflux Disease
Phase of Trial: Phase III
Latest Information Update: 01 Apr 2018
At a glance
- Drugs Vonoprazan (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Sponsors Takeda
- 26 Mar 2018 Status changed from active, no longer recruiting to completed.
- 25 Feb 2018 Planned End Date changed from 21 Apr 2018 to 27 Feb 2018.
- 25 Feb 2018 Planned primary completion date changed from 21 Apr 2018 to 27 Feb 2018.